Perioperative pharmacotherapy for endoprosthetics: potential of chondroitin sulfate and glucosamine sulfate
https://doi.org/10.17749/2070-4909/farmakoekonomika.2022.136
Abstract
Joint endoprosthetics is a treatment of choice for patients with decompensated osteoarthritis (OA), who have exhausted the possibilities of pharmacotherapy and other methods of conservative treatment. Preparation for endoprosthetics and rehabilitation after surgery usually includes measures to improve the muscle condition and local blood circulation in the joint area, and if necessary, pain management. The unique spectrum of anti-inflammatory effect of chondroprotectors based on chondroitin sulfate and glucosamine sulfate includes inhibition of NF-κB cascade, toll-like receptors, pro-inflammatory cytokines, metalloproteinases, and significantly alleviates the course of OA. Reducing the severity of OA is important for preparing for surgery, subsequent rehabilitation, and preventing the revision surgery.
About the Authors
I. Yu. Torshin
Federal Research Center “Informatics and Management”, Russian Academy of Sciences
Russian Federation
Russian Federation
PhD (Phys. Math.), PhD (Chem.), Senior Researcher,
4 Vavilov Str., Moscow 2119333
T. B. Minasov
Bashkir State Medical University
Russian Federation
Russian Federation
Dr. Med. Sc., Professor, Chair of Traumatology and Orthopedics with the course of the Institute of Additional Professional Education,
3 Lenin Str., Ufa 450008
N. V. Zagorodniy
Priorov National Medical Research Center of Traumatology and Orthopedics;
Peoples' Friendship University of Russia
Russian Federation
Russian Federation
Dr. Med. Sc., Corresponding Member of RAS, Professor, Chair of Traumatology and Orthopedics, Head of Joint Replacement Clinic, 10 Priorov Str., Moscow 127299;
Chief of Chair of Traumatology and Orthopedics, Faculty of Medicine, 6 Miklukho-Maklay Str., Moscow 117198
A. M. Lila
Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
Dr. Med. Sc., Professor, Director,
34А Kashirskoye Shosse, Moscow 115522
O. A. Gromova
Federal Research Center “Informatics and Management”, Russian Academy of Sciences
Russian Federation
Russian Federation
Dr. Med. Sc., Professor, Research Supervisor,
4 Vavilov Str., Moscow 2119333
References
1. Sukhikh S., Noskova S., Ivanova S., et al. Chondroprotection and molecular mechanism of action of phytonutraceuticals on osteoarthritis. Molecules. 2021; 26 (8): 2391. https://doi.org/10.3390/molecules26082391.
2. Aweid O., Haider Z., Saed A., Kalairajah Y. Treatment modalities for hip and knee osteoarthritis: a systematic review of safety. J Orthop Surg (Hong Kong). 2018; 26 (3): 2309499018808669. https://doi.org/10.1177/2309499018808669.
3. Kellesarian S.V., Malignaggi V.R., Kellesarian T.V., et al. Does incorporating collagen and chondroitin sulfate matrix in implant surfaces enhance osseointegration? A systematic review and metaanalysis. Int J Oral Maxillofac Surg. 2018; 47 (2): 241–51. https://doi.org/10.1016/j.ijom.2017.10.010.
4. Bauza-Mayol G., Quintela M., Brozovich A., et al. Biomimetic scaffolds modulate the posttraumatic inflammatory response in articular cartilage contributing to enhanced neoformation of cartilaginous tissue in vivo. Adv Healthc Mater. 2022; 11 (1): e2101127. https://doi.org/10.1002/adhm.202101127.
5. Wartenberg A., Weisser J., Schnabelrauch M. Glycosaminoglycanbased cryogels as scaffolds for cell cultivation and tissue regeneration. Molecules. 2021; 26 (18): 5597. https://doi.org/10.3390/molecules26185597.
6. Lee S., Choi J., Youn J., et al. Development and evaluation of gellan gum/silk fibroin/chondroitin sulfate ternary injectable hydrogel for cartilage tissue engineering. Biomolecules. 2021; 11 (8): 1184. https://doi.org/10.3390/biom11081184.
7. Sharma S., Madhyastha H., Laxmi Swetha K., et al. Development of an in-situ forming, self-healing scaffold for dermal wound healing: in-vitro and in-vivo studies. Mater Sci Eng C Mater Biol Appl. 2021; 128: 112263. https://doi.org/10.1016/j.msec.2021.112263.
8. Lin T.S., Hsieh C.H., Kuo C., et al. Sulfation pattern of chondroitin sulfate in human osteoarthritis cartilages reveals a lower level of chondroitin-4-sulfate. Carbohydr Polym. 2020; 229: 115496. https://doi.org/10.1016/j.carbpol.2019.115496.
9. Silva F.S. Jr., Yoshinari N.H., Castro R.R., et al. Combined glucosamine and chondroitin sulfate provides functional and structural benefit in the anterior cruciate ligament transection model. Clin Rheumatol. 2009; 28 (2): 109–17. https://doi.org/10.1007/s10067-008-0988-8.
10. Lila A.M., Gromova O.A., Torshin I.Yu., Nazarenko A.G., Gogolev A.Yu. Molecular effects of chondroguard in osteoarthritis and herniated discs. Neurology, Neuropsychiatry, Psychosomatics. 2017; 9 (3): 88–97 (in Russ.). https://doi.org/10.14412/2074-2711-2017-3-88-97.
11. Torshin I.Yu., Gromova O.A., Lila A.M., et al. Toll-like receptors as a part of osteoarthritis pathophysiology: anti-inflammatory, analgesic and neuroprotective effects. Neurology, Neuropsychiatry, Psychosomatics. 2021; 13 (4): 123–9 (in Russ.). https://doi.org/10.14412/2074-2711-2021-4-123-129.
12. Gromova O.A., Torshin I.Yu., Lila A.M., et al. Standardised forms of chondroitin sulfate as a pathogenetic treatment of osteoarthritis in the context of post-genomic studies. Modern Rheumatology Journal. 2021; 15 (1): 136–43 (in Russ.). https://doi.org/10.14412/1996-7012-2021-1-136-143.
13. Uitterlinden E.J., Jahr H., Koevoet J.L., et al. Glucosamine decreases expression of anabolic and catabolic genes in human osteoarthritic cartilage explants. Osteoarthritis Cartilage. 2006; 14 (3): 250–7. https://doi.org/10.1016/j.joca.2005.10.001.
14. Kirchanov V.A., Fedorishchev V.A. Indications and contraindications for endoprosthetics of large joints of limbs. Guidelines for doctors. Voronezh; 2017 (in Russ.).
15. Obertacke U., Nast-Kolb D. Specific features of accidents, injuries and surgical care in the elderly. Unfallchirurg. 2000; 103 (3): 227–2 (in German). https://doi.org/10.1007/s001130050527.
16. Jawhar A., Skeirek D., Stetzelberger V., Obertacke U. Influence of the tourniquet on pain and function in total knee arthroplasty: a systematic review and meta-analysis. Z Orthop Unfall. 2020; 158 (6): 630–40. https://doi.org/10.1055/a-0983-3808.
17. Schneider H., Maheu E., Cucherat M. Symptom-modifying effect of chondroitin sulfate in knee osteoarthritis: a meta-analysis of randomized placebo-controlled trials performed with Structum®. Open Rheumatol J. 2012; 6: 183–9. https://doi.org/10.2174/1874312901206010183.
18. Meng Z., Liu J., Zhou N. Efficacy and safety of the combination of glucosamine and chondroitin for knee osteoarthritis: a systematic review and meta-analysis. Arch Orthop Trauma Surg. 2022; Jan 13. https://doi.org/10.1007/s00402-021-04326-9.
19. Gregori D., Giacovelli G., Minto C., et al. Association of pharmacological treatments with long-term pain control in patients with knee osteoarthritis: a systematic review and meta-analysis. JAMA. 2018; 320 (24): 2564–79. https://doi.org/10.1001/jama.2018.19319.
20. Honvo G., Reginster J.Y., Rabenda V., et al. Safety of symptomatic slow-acting drugs for osteoarthritis: outcomes of a systematic review and meta-analysis. Drugs Aging. 2019; 36 (Suppl. 1): 65–99. https://doi.org/10.1007/s40266-019-00662-z.
21. Maiko O.Y. Pharmacoeconomic aspects of using chondroitin sulfate in the outpatient treatment of patients with osteoarthritis. Health Care Standardization Problems. 2020; 3-4: 72–7 (in Russ.). https://doi.org/10.26347/1607-2502202003-04072-077.
22. Torshin I.Yu., Lila A.M., Naumov A.V., et al. Meta-analysis of clinical trials of osteoarthritis treatment effectiveness with Chondroguard. FARMAKOEKONOMIKA. Sovremennaya farmakoekonomika i farmakoepidemiologiya / FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2020; 13 (4): 388–99 (in Russ.). https://doi.org/10.17749/2070-4909/farmakoekonomika.2020.066.
23. Crovace A., Lacitignola L., Miolo A., Fanizzi F.P. Surgery plus chondroprotection for canine cranial cruciate ligament (CCL) rupture: a proton-NMR study. Vet Comp Orthop Traumatol. 2006; 19 (4): 239–45.
24. Kamarul T., Ab-Rahim S., Tumin M., et al. A preliminary study of the effects of glucosamine sulphate and chondroitin sulphate on surgically treated and untreated focal cartilage damage. Eur Cell Mater. 2011; 21: 259–71. https://doi.org/10.22203/ecm.v021a20.
25. Sobue Y., Kojima T., Kurokouchi K., et al. Prediction of progression of damage to articular cartilage 2 years after anterior cruciate ligament reconstruction: use of aggrecan and type II collagen biomarkers in a retrospective observational study. Arthritis Res Ther. 2017; 19 (1): 265. https://doi.org/10.1186/s13075-017-1471-1.
26. Bruyere O., Pavelka K., Rovati L.C., et al. Total joint replacement after glucosamine sulphate treatment in knee osteoarthritis: results of a mean 8-year observation of patients from two previous 3-year, randomised, placebo-controlled trials. Osteoarthritis Cartilage. 2008; 16 (2): 254–60. https://doi.org/10.1016/j.joca.2007.06.011.
Review
For citations:
Torshin I.Yu., Minasov T.B., Zagorodniy N.V., Lila A.M., Gromova O.A. Perioperative pharmacotherapy for endoprosthetics: potential of chondroitin sulfate and glucosamine sulfate. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2022;15(1):162-169. (In Russ.) https://doi.org/10.17749/2070-4909/farmakoekonomika.2022.136
Views:
1801
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 